All the Therapeutic System Drugs
Recombinant Human Erythropoietin. Darbepoetin Alfa 10, 20, 30, 40, 50, 60, 80, 100, 150, 300, 500 mcg. PREFILL. SYRINGES (for single use only, with/out automat. needle guard): 4 x 10 μg; 20 μg; 30 μg; 40 μg; 50 μg; 60 μg; 80 μg; 100 μg, 150 μg; 1 x 300 μg, 500 μg. For I.V. and S.C. admin. Similar efficacy in I.V. and S.C. admin.
PREFILL. PEN (SureClick) (single use only): 1 x 20 μg, 40 μg, 60 μg, 80 μg, 100 μg,150 μg, 300 μg, 500 μg. S.C. admin only.
Tmt. anem. assoc. with chron. ren. fail. in adults and pediatric subjects 1 yrs of age and over. Aranesp 150, 300, 500 -also tmt. anem. in adult cancer pts. with non-myeloid malignancies receiv. chemother.
C/I: Hpersenes. Poorly control. hypertens.
Urinary Antispasmodic. Mirabegron 25 mg, 50 mg. PROLONG REL. TABS.: 30×25, 50 mg.
Adult. (include. elder. pts.) 50 mg once
daily with/without food.
Sympt. tmt. of urgency, incr. micturition
freq. and/or urgency incont. as may occur
in adult pts. with OAB syndr.
Creation date March 2020
Recombinant Human Erythropoietin. Epoeitin Alpha 1,000 IU/0.5 ml, 2,000 IU/1 ml, 3,000 IU/0.3 ml, 4,000 IU/0.4 ml, 5,000 IU/0.5 ml, 6,000 IU/0.6 ml, 8,000 IU/0.8 ml, 10,000 IU/1 ml, 20,000 IU/0.5 ml, 30,000 IU/0.75 ml, 40,000 IU/1 ml. Prefilled syringes (ready to
20000IU/0.5ml, 30000IU/0.75ml &
Tmt. and dosage has to be initiated
and adjust. individ. for each pt. accord.
to the med. condit.
Tmt. of symptom. anaemia assoc.with
chron.renal fail.(CRF) in adult and
paediatric pts.:- Tmt. of anaemia assoc.
with chron. ren. fail.in paed. and adult pts.
on haemodialysis and adult pts. on
periton. dialysis.- Tmt. of sev. anaemia of
renal origin accomp. by clin. sympt. in
adult pts. with ren. insuffic. not yet
undergoing dialysis. Tmt. of anaemia and
reduct. of transfus. requirem. in adult pts.
receiv. chemother. for solid tumour.,
malign. lymphoma or multiple myeloma,
and at risk of transfus. as assessed by the
patient’s gener. status (e.g. cardiovascular
status, pre existing anaemia at the start of
chemother.). Binocrit can be used to
increase the yield of autologous blood from pts. in a predonation programme. Its
use in this indicat. must be balanced
against the reported risk of thromboemb.
events. Tmt. should only be given to noniron
defic. pts. with moder. anaem.
(haemoglobin (Hb) 10 13 g/dl (6.2 8.1
mmol/l)), if blood saving procedur. are not
available or insuffic. when the scheduled
major elect. surg. requires a large volume
of blood (4 or more units of blood for
females or 5 or more units for males). The
drug can be used to reduce exposure to
allogeneic blood transfus. in adult non
iron defic. pts. prior to major elective
orthopaedic surg., having a high perceived
risk for transfus. complicat. Use should be
restricted to pts. with moder. anaemia (e.g.
Hb 10 13 g/dl) who do not have an
autolog. predonation programme
available and with an expect. blood loss of
900 to 1800 ml.
C/I: Hypersens., pts. who develop PRCA
follow. tmt. with any erythropoietin
should not receive this drug or any other